Haoxi Health Technology Limited Announces Closing of $9,600,000 Initial Public Offering

Rhea-AI Summary

Haoxi Health Technology Limited (HAO) has closed its initial public offering, raising $9,600,000 from the sale of 2,400,000 Class A ordinary shares at an IPO price of $4.00 per share. The Company's shares began trading on Nasdaq under the ticker symbol 'HAO' on January 26, 2024. The underwriters have an option to purchase an additional 360,000 shares. The proceeds will be used for working capital, acquiring or investing in technologies, solutions, or businesses, and hiring experienced employees. The registration statement was filed with the SEC on August 25, 2023, and declared effective on January 25, 2024.

Insights

Financial Analyst

The completion of Haoxi Health Technology Limited's initial public offering (IPO) represents a significant capital infusion, which can be pivotal for the company's growth trajectory. The successful raising of $9.6 million in gross proceeds before expenses indicates investor confidence in the firm's business model and future prospects. The allocation of funds towards working capital, technological acquisitions and talent hiring is a strategic move that could enhance operational efficiency and competitive edge. However, investors should consider the dilutive effect of additional shares on existing equity and the potential for share price volatility as the market assimilates the new public entity.

Moreover, the option granted to EF Hutton to purchase additional shares to cover over-allotments is a common practice in IPOs known as a 'greenshoe' option. This mechanism provides stability to the stock price post-IPO by allowing the underwriter to manage excessive market demand. While this can be seen as a safety net for the new issue, it also implies a potential further dilution if the option is exercised. Investors should monitor the company's post-IPO performance closely, particularly its use of proceeds and the impact on its financials.

Market Research Analyst

Haoxi Health Technology Limited's entry into the Nasdaq Capital Market is a strategic decision that can provide the company with greater visibility and access to capital in the global market. The selection of Nasdaq, known for its high concentration of tech stocks, could align with the company's tech-focused business objectives. The IPO pricing at $4.00 per share sets a benchmark for the company's valuation and market reception in the subsequent trading sessions will be a key indicator of investor sentiment.

Investors should evaluate the competitive landscape of online marketing solutions within the tech industry, especially in the context of China's regulatory environment which has seen increased scrutiny in recent years. The company's ability to navigate these regulations while investing in new technologies and business solutions will be critical for its sustained growth. The potential for international expansion, given the Nasdaq listing, also opens the company to a broader range of market dynamics and competition.

Legal Expert

The involvement of specialized legal counsel in the IPO process, such as Hunter Taubman Fischer & Li LLC and Pryor Cashman LLP, underscores the legal complexities inherent in going public, particularly for a company based in China listing on a U.S. exchange. Compliance with SEC regulations and adherence to the legal requirements of both countries is paramount. The effective declaration of the registration statement by the SEC is a testament to the company's due diligence in meeting these stringent standards.

Prospective investors should be cognizant of the legal frameworks governing the company's operations, as changes in regulatory policies can significantly affect the company's business model and stock performance. The transparency provided by the SEC filings, including the prospectus, offers a detailed view of the company's financials, risks and strategic plans, which are essential for making informed investment decisions.

BEIJING, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the closing of its initial public offering (the "Offering") of 2,400,000 Class A ordinary shares (the "Ordinary Shares") at an initial public offering price of $4.00 per share for total gross proceeds of $9,600,000, before deducting underwriting discounts and other offering expenses. The Offering closed on January 30, 2024, and the Ordinary Shares began trading on Nasdaq Capital Market on January 26, 2024, under the ticker symbol "HAO". The Company has granted EF Hutton LLC (“EF Hutton”), the representative of the underwriters, an option, within 45 days from the closing date of the Offering, to purchase up to an additional 360,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the over-allotments, if any. The Offering has been conducted on a firm commitment basis.

EF Hutton acted as the sole bookrunner for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. counsel to the Company, and Pryor Cashman LLP acted as U.S. counsel to EF Hutton, in connection with the Offering.

The Company intends to use the proceeds from this Offering for 1) working capital and general corporate purposes; 2) acquiring or investing in technologies, solutions, or businesses; and 3) hiring experienced employees.

The registration statement on Form F-1 (File No. 333-274214) relating to the Offering, as amended, was filed with the U.S. Securities and Exchange Commission (the "SEC") initially on August 25, 2023, and was declared effective by the SEC on January 25, 2024. The Offering was made only by means of a prospectus. Copies of the final prospectus related to the Offering may be obtained, from EF Hutton, Attn: Syndicate Department, 590 Madison Avenue, 39^th Floor, New York, NY 10022, or via email at syndicate@efhutton.com or telephone at (212) 404-7002. In addition, a copy of the final prospectus can also be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Haoxi Health Technology Limited

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: http://ir.haoximedia.com.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Representative of the underwriters
EF Hutton LLC
Ms. Stephanie Hu, Head of Asia, Investment Banking
Email：syndicate@efhutton.com  

Investor Relations

WFS Investor Relations Inc.
Janice Wang, Managing Partner
Email: services@wealthfsllc.com 
Phone: +86 13811768599
+1 628 283 9214

FAQ

What is the ticker symbol for Haoxi Health Technology Limited?

The ticker symbol for Haoxi Health Technology Limited is 'HAO'.

How many shares were sold in the initial public offering?

2,400,000 Class A ordinary shares were sold in the initial public offering.

What was the IPO price per share?

The IPO price per share was $4.00.

Where will the Company's shares trade?

The Company's shares will trade on the Nasdaq Capital Market.

What will the proceeds from the Offering be used for?

The proceeds will be used for working capital, acquiring or investing in technologies, solutions, or businesses, and hiring experienced employees.

When was the registration statement declared effective by the SEC?

The registration statement was declared effective by the SEC on January 25, 2024.